Background
Cristina Adriana Popa
Advance-HTN: Return of the systolic order – ...

This week, we will discuss a NEJM trial on uncontrolled hypertension: lorundrostat, an aldosterone synthase inhibitor, aims at the hormonal dark side driving resistance.

Advance-HTN: Return of the systolic order – Lorundrostat’s role in restoring balance
Background
swapnil hiremath
Double Trouble: ddAVP and the Bleeding Biopsy

This week, we will discuss a double header: two single centre ddAVP trials in kidney biopsy from India.

Double Trouble: ddAVP and the Bleeding Biopsy
Background
Cristina Adriana Popa
Kidney Allografts-Play With Fire, Get Burned

This week, we will discuss the prognostic role of microvascular inflammation in kidney transplantation. Can the capillaries whisper their damage in lesions before antibodies speak? Maybe this study compels us to treat the injury we see, not just the disease we can name…

Kidney Allografts-Play With Fire, Get Burned
Background
swapnil hiremath
Metformin- Should I Stay or Should I Go

This week, we will discuss another target trial emulation study. The FDA says to stop metformin at a GFR of 30. Are they right?

Metformin- Should I Stay or Should I Go
Background
Brian Rifkin
KDIGO 2025 ADPKD Guidelines Review

This week, we will discuss the first iteration of KDIGO’s 2025 guidelines on ADPKD.  These guidelines are a result of a decade of global collaboration between physicians, researchers, advocates, and patients. The guidelines incorporate ADPKD-specific care as well as many general CKD management practice points.


KDIGO 2025 ADPKD Guidelines Review

Dare I say that last night was the best #NephJC yet?

Wow! What a great discussion!

We had 22 participants, including a number of new faces. This is the highest participation since we teamed with the cardiologists for POSEIDON in NephJC #5. The people also participated with 308 tweets, also the second most, next to POSEIDON, ever. Great #NephJC. Thank you everyone.

Here are the numbers and links to the analytics and transcript.

What is #NephJC Live?

So this is the obvious question. The idea is still not fully formed but the pitch to ASN was that we would find some scientists who are presenting at an ASN poster session that would like a venue to discuss their data in front of an intelligent, engaged and honestly, quite handsome audience. The NephJC Live session is on Saturday, so everybody's embargo will be expired and authors will be free discuss their research.

That said we are looking for scientists eager to present at NephJC. If you are interested or know someone with great data that did not get an opportunity to discuss it with an oral presentation have them contact nephrologyjc@gmail.com.

CJASN eJC goes to Twitter

This month eJC is talking about Nephrology Fellowship. The article they are using is here and was written by Jeffrey Barns, Stuart Linas and Mitchell Rosner.

As part of the discussion eJC did their first TweetChat on September 10th. It was great, with an excellent turn-out and spirited discussion. Nephrology fellow Amar Bansal lead the discussion. NephJC produced a curated transcript with Storify. Here it is:


Tweet of the (last) Week

Every so often a single tweet neatly encompasses the entire discussion. This happened at last week's aPLA2R TweetChat. This is the tweet that won:

But to properly set it up you need to additional tweets:

I love the idea of aPLA2R as a viral load, a leading indicator of idiopathic membranous nephropathy. Nice work Christos. For your effort we will be sending you a #NephJC coffee mug.

Want your own NephJC coffee mug?

Tweet better!

Next opportunity is tonight 9pm Eastern.

Tonight's NephJC Tweetchat is all about aPLA2R

aPLA2R is the first blood test specifically for nephrotic syndrome. It has recently been licensed by the FDA and we want to have an open and frank discussion on how this test may be used in clinical medicine. To aid in this discussion we will be looking at two papers.

The first was highlighted by CJASN's eJC and was covered summarized by Joel Topf and his Fellow, Bilal Saleem:

The second article was published this past Spring in NDT. It is an industry sponsored trial of ACTH for the treatment of membranous nephropathy. Swapnil Hiremath summarized it for #NephJC

And additionally here is a link to the KDIGO Glomerulonephritis Recommendations.

Please join us on Twitter at 9pm Eastern Daylight. Use the hashtag #NephJC.

NephJC made the FOAM Reduction e-mail mailing list

FOAM Reduction bills itself as a Twitter-free means of receiving FOAM (free open access medical education). The July 25th edition touched on the recent hyponatremia guidelines and included a shout out to our TweetChat. We are honored.

“Hyponatremia

Rumor has it that hyponatremia is near the top of UpToDate’s most searched list. Probably because it is so damn common (15-20% of hospital admissions) and the algorithm is a pain. Enter the Hyponatremia Guideline Development Group (I want to party with these guys), who recently published a new clinical practice guideline for diagnosis and treatment of hyponatremia. It is surprisingly easy to follow, by eliminating volume status guesses and depending on urine osmolality, urine sodium to determine the etiology of water excess.

The guideline can be found here and if you want a more expert take on the guidelines, a group of nephrologists performed a Twitter-based journal club (#NephJC, @nephjc) dissection on the guideline here.

I included the diagnosis algorithm from the new guideline below, along with the algorithm I see used most often.”